Search alternatives:
point decrease » point increase (Expand Search)
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
a mean » _ mean (Expand Search)
point decrease » point increase (Expand Search)
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
a mean » _ mean (Expand Search)
-
1821
-
1822
-
1823
-
1824
-
1825
-
1826
-
1827
-
1828
List of selected metabolites that associate with diabetes at q-values <0.05 using log-scaled metabolite concentrations and assuming a linear model; %change is the increase or decrease of the mean in the diabetes group with respect to the control group; eta<sup>2</sup> is the proportion of the total variance that can be explained by the factor “diabetes” in the linear model; N is the number of valid data points that entered the analysis; the platform on which the corresponding metabolite was measured is indicated by the first letter of the provider: B = Biocrates, C = Chenomx, M = Metabolon.
Published 2010“…<p>List of selected metabolites that associate with diabetes at q-values <0.05 using log-scaled metabolite concentrations and assuming a linear model; %change is the increase or decrease of the mean in the diabetes group with respect to the control group; eta<sup>2</sup> is the proportion of the total variance that can be explained by the factor “diabetes” in the linear model; N is the number of valid data points that entered the analysis; the platform on which the corresponding metabolite was measured is indicated by the first letter of the provider: B = Biocrates, C = Chenomx, M = Metabolon.…”
-
1829
-
1830
-
1831
-
1832
-
1833
-
1834
VRK1 overexpression is seen in human breast cancer and is associated with decreased relapse-free survival.
Published 2018“…Data for cancer subtypes are shown in boxes numbered 1–11: 1: benign breast neoplasm (rank 6459, 1.4 fold-change, NS), 2: breast carcinoma (rank 833, 1.5 fold-change, p = 3.83x10<sup>-5</sup>), 3: breast phyllodes tumor (rank 512, 1.2 fold-change, p = 0.002), 4: ductal breast carcinoma in situ (rank 1969, 1.5 fold-change, p = 0.002), 5: invasive breast carcinoma (rank 1060, 1.6 fold-change, p = 1.28x10<sup>-5</sup>), 6: invasive ductal and invasive lobular breast carcinoma (rank 941, 1.5 fold-change, p = 6.76x10<sup>-22</sup>), 7: invasive ductal breast carcinoma (rank 613, 1.5-fold change, p = 2.71x10<sup>-71</sup>), 8: invasive lobular breast carcinoma (rank 947, 1.3 fold-change, p = 3.64x10<sup>-28</sup>), 9: medullary breast carcinoma (rank 400, 1.8 fold-change, p = 3.25x10<sup>-12</sup>), 10: mucinous breast carcinoma (rank 1932, 1.4 fold-change, p = 7.41x10<sup>-10</sup>) and 11: tubular breast carcinoma (rank 1253, 1.4 fold-change, p = 1.24x10<sup>-17</sup>). …”
-
1835
-
1836
Hsp72 overexpression decreases total NF-κB-p65 in resting cells and reduces steady state IκBα protein levels.
Published 2014“…Gray data points are rescaled from <a href="http://www.ploscompbiol.org/article/info:doi/10.1371/journal.pcbi.1003471#pcbi-1003471-g001" target="_blank">Fig. 1B</a>. …”
-
1837
-
1838
Pan-JAK inhibitor P6 decreased ISG expression and increased susceptibility of BEAS-2B cells to H1N1 influenza virus infection.
Published 2014“…BEAS-2B cells were pre-treated with P6 at a final concentration of 2.5 or 5 µM for 24 h and infected with H1N1 influenza virus at 1.0 MOI (based on MDCK cells). …”
-
1839
Possible Points of Canonical Wnt Inhibition.
Published 2015“…<p>This study has highlighted six possible points of canonical Wnt inhibition occurring in HSCs. (1) Predominantly non-canonical ligand expression. …”
-
1840